or Try an Advanced Search...

    Technical Analysis for THAR - Tharimmune, Inc.

    Grade Last Price % Change Price Change
    F 0.41 10.62% 0.04
    THAR closed up 10.62 percent on Wednesday, May 8, 2024, on 80 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical THAR trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    20 DMA Resistance Bearish 10.62%
    Inside Day Range Contraction 10.62%
    Gapped Up Strength 10.62%
    Older End-of-Day Signals for THAR ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 15 hours ago
    60 Minute Opening Range Breakout about 15 hours ago
    Up 2% about 15 hours ago
    Up 1% about 15 hours ago
    Possible NR7 about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    THAR Chart by TradingView
    Basic chart:

    Profile

    Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Solid Tumors Antibodies Autoimmune Disease Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis

    Is THAR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 2 Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
    Apr 23 Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
    Apr 15 Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
    Mar 6 Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
    Mar 5 Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
    Feb 20 Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
    Feb 5 Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
    Jan 29 Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
    Dec 19 Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
    Dec 11 Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
    See more THAR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.4725
    52 Week Low 0.3439
    Average Volume 247,629
    200-Day Moving Average 2.76
    50-Day Moving Average 0.40
    20-Day Moving Average 0.38
    10-Day Moving Average 0.37
    Average True Range 0.02
    RSI (14) 58.85
    ADX 9.77
    +DI 21.62
    -DI 14.47
    Chandelier Exit (Long, 3 ATRs) 0.38
    Chandelier Exit (Short, 3 ATRs) 0.43
    Upper Bollinger Bands 0.40
    Lower Bollinger Band 0.35
    Percent B (%b) 1.13
    BandWidth 14.50
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0039
    Fundamentals Value
    Market Cap 1.03 Million
    Num Shares 2.53 Million
    EPS -15.50
    Price-to-Earnings (P/E) Ratio -0.03
    Price-to-Sales 0.00
    Price-to-Book 0.67
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.48
    Resistance 3 (R3) 0.47 0.44 0.47
    Resistance 2 (R2) 0.44 0.42 0.44 0.46
    Resistance 1 (R1) 0.43 0.41 0.43 0.43 0.46
    Pivot Point 0.39 0.39 0.40 0.40 0.39
    Support 1 (S1) 0.38 0.38 0.39 0.39 0.36
    Support 2 (S2) 0.35 0.37 0.35 0.35
    Support 3 (S3) 0.33 0.35 0.35
    Support 4 (S4) 0.34